Clinical meaning
Cervical carcinogenesis is driven by persistent infection with high-risk HPV genotypes, predominantly HPV 16 and 18, which account for approximately 70% of invasive cervical cancers. Upon integration into the host genome, the viral oncoproteins E6 and E7 exert their transformative effects through distinct molecular mechanisms. E6 binds to the E6-associated protein (E6AP), a ubiquitin ligase, forming a complex that targets the p53 tumor suppressor protein for proteasomal degradation, abolishing p53-mediated cell cycle arrest and apoptosis. E7 binds and destabilizes retinoblastoma protein (pRb), releasing E2F transcription factors that drive uncontrolled S-phase entry and DNA replication. The combined loss of p53 and pRb function creates genomic instability, accumulation of secondary mutations, and progressive neoplastic transformation through CIN grades. The tumor microenvironment undergoes immunoediting, with HPV-infected cells evading immune clearance through downregulation of MHC class I molecules, secretion of immunosuppressive cytokines (IL-10, TGF-beta), and recruitment of regulatory T cells. Squamous cell carcinoma accounts for approximately 70% of invasive cervical cancers, while adenocarcinoma (arising from endocervical glandular epithelium) accounts for approximately 25% and is increasing in incidence due to relative insensitivity to cytologic screening. Lymphovascular space invasion (LVSI) is a critical histopathologic prognostic factor predicting lymph node metastasis and disease recurrence.